HCATNasdaqServices-Computer Programming, Data Processing, Etc.Fiscal year ends December 31
Health Catalyst, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.71−0.02 (-0.87%)
Close on Oct 19, 2026
- Market cap
- $126.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
48.7%+0.7 pts over 5 years
Operating margin
-51.7%−0.8 pts over 5 years
Net margin
-57.2%+3.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.5% | +4.0% | +10.5% | – | |
| Gross profit | +7.7% | +4.4% | +10.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -48.3% | -58.3% | |
| Return on assets | – | -26.1% | -26.1% | |
| Current ratio | – | 3.75 | 1.89 | |
| Debt to equity | – | 0.61 | 0.62 | |
| Net debt to EBITDA | – | -1.00× | -0.93× | |
| Capex to revenue | – | 4.1% | 0.3% | |
| Diluted shares | – | 40M | 70M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Health Catalyst generated $106.76M from operations and spent $31.64M on capital expenditure, dividends and share buybacks. 52% of that went back into the business.
Generated
$106.76M
Used
$31.64M
Capital expenditure$16.44M52%Dividends$00%Share buybacks$15.20M48%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-57.2%
×Asset turnover0.46×
×Equity multiplier2.23×
=Return on equity, FY2025-58.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -57.2% | 0.46× | 2.23× | -58.3% |
| FY2024 | -22.7% | 0.39× | 2.13× | -19.0% |
| FY2023 | -39.9% | 0.41× | 1.84× | -29.8% |
| FY2022 | -49.7% | 0.35× | 1.67× | -29.0% |
| FY2021 | -63.3% | 0.34× | 1.77× | -38.4% |
| FY2020 | -60.9% | 0.43× | 1.85× | -48.3% |
| FY2019 | -38.8% | 0.75× | -2.37× | 69.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$177.97M
- Cash generatingOperating cash flow above zero$731.00K
- Return on assets improvedROA up on the prior year-9.9% → -20.7%
- Earnings backed by cashOperating cash flow above net income$731.00K vs -$177.97M
- Less leverageLong-term debt to assets fell17.6% → 30.2%
- Better liquidityCurrent ratio rose1.43 → 1.89
- No dilutionShare count did not rise60M → 70M
- Gross margin improvedGross margin up on the prior year45.92% → 48.75%
- More efficientAsset turnover rose0.44 → 0.36